Engineering aspects of stents design and their translation into clinical practice.
The implantation of coronary stents is a relevant part of interventional procedures for percutaneous revascularization. The wide acceptance of coronary stenting was based on the results of two highly significant trials which have shown the superiority of stenting over balloon angioplasty in terms of reduction of angiographic restenosis and need for repeated intervention in focal lesions and large coronary arteries. Since then, the growing use of stent market was impressive. A rapidly increasing number of different stent type with different material and designs has been introduced in the market both for bare metal stent and drug eluting stent. This review will summarize the different components of stent design that are important in term of biological response of the arterial wall and clinical outcome. In addition, new stent platforms, mainly represented by the biodegradable stent will be shortly reviewed since it may provide in the near future a more "physiological" answer to stent implantation, reducing vascular injury and accelerating vessel healing with consequent improving in clinical outcome.
Sangiorgi
Giuseppe
G
Ospedale San Raffaele, Via Olgettina 64, 20132 Milan, Italy. sangiorgi@emocolumbus.it
Melzi
Gloria
G
Agostoni
Pierfrancesco
P
Cola
Clarissa
C
Clementi
Fabrizio
F
Romitelli
Paolo
P
Virmani
Renu
R
Colombo
Antonio
A
D020341:Absorbable Implants; D015906:Angioplasty, Balloon, Coronary; D002986:Clinical Trials as Topic; D020099:Coated Materials, Biocompatible; D023921:Coronary Stenosis / Q000628:therapy*; D004343:Drug Implants; D004867:Equipment Design; D006801:Humans; D015337:Multicenter Studies as Topic; D017239:Paclitaxel / Q000008:administration & dosage; D020123:Sirolimus / Q000008:administration & dosage; D015607:Stents / Q000009:adverse effects / Q000145:classification; D016896:Treatment Outcome
D020099:Coated Materials, Biocompatible; D004343:Drug Implants; D017239:Paclitaxel; D020123:Sirolimus